XOMA Corporation
XOMAO
NASDAQ Global Market25.36
USD
-0.01
- -
CIK
0000791908
ISIN
US98419J4040
CUSIP
98419J404
Return %
Stock
S&P500
1Y
0.63
26.53
3Y
7.50
76.60
5Y
4.41
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Owen Hughes Jr.
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2200 Powell Street EmeryVille CA United States of America 94608
- IPO Date
- Apr 12, 2021
- CIK
- 0000791908
- Website
- xoma.com
- Similar Companies
- Business
- XOMA Royalty Corporation operates as a biotechnology royalty aggregator focused on acquiring economic rights to future milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its portfolio includes over 120 assets that are licensed to and developed by other biotechnology and pharmaceutical companies, with commercial products such as VABYSMO (faricimab-svoa) for wet AMD and diabetic macular edema, OJEMDA (tovorafenib), MIPLYFFA (arimoclomol) for Niemann-Pick Type C disease, XACIATO (clindamycin phosphate) vaginal gel 2%, IXINITY (coagulation factor IX recombinant), and DSUVIA (sufentanil sublingual tablet) for acute pain. The company operates primarily in the United States and the Asia Pacific regions. Founded in 1981, XOMA is headquartered in Emeryville, California. Recent major changes include the July 2024 rebranding from XOMA Corporation to XOMA Royalty Corporation to better reflect its role as a royalty aggregator. In 2025, XOMA completed the acquisition of LAVA Therapeutics, incorporating two early-stage bispecific antibodies developed in collaboration with Johnson & Johnson and Pfizer, aimed at enhancing their oncology portfolio with significant future milestone and royalty potential. Additionally, the company acquired royalty rights from HilleVax and entered a strategic financing partnership with Blue Owl Capital securing up to $140 million to support asset acquisition and stock repurchases. XOMA also launched a stock repurchase program in 2024 following a $140 million transaction related to VABYSMO royalties and has expanded its portfolio by obtaining royalty streams from Organon's marketing of XACIATO vaginal gel. These moves collectively underscore XOMA’s strategic pivot towards enhancing cash flow through diversified royalty assets and partner-funded programs. XOMA’s business model centers on developing and monetizing a broad portfolio of biopharmaceutical assets in various clinical stages, with a focus on early to mid-stage clinical assets promising commercial sales potential. It targets biopharmaceutical companies by providing non-dilutive funding via milestone and royalty acquisitions, serving markets including rare diseases, oncology, and specialty drug therapies. Its strategic partnerships leverage collaborations with industry leaders to maximize value from their royalty and milestone rights, positioning the company as a significant player within the biotechnology and healthcare sectors. XOMA’s approach emphasizes sustainable cash flow generation and value creation through a diversified portfolio supported by ongoing clinical development and commercialization activities.
XOMA Co. (NASDAQ:XOMAO) Short Interest Update
XOMA (NASDAQ:XOMAO) Trading 0.1% Higher – Still a Buy?
XOMA Co. (NASDAQ:XOMAO) Short Interest Update